COMPARISON OF SURVIVAL PERIODS AND RESPONSE IN THREE MODES OF TREATMENT FOR Ca ESOPHAGUS AT CENAR QUETTA
AbstractBackground: Esophageal cancer is a fatal disease, with mortality matching the incidence. Balochistan province and Afghanistan happen to fall in the "Esophageal Cancer Belt". This study was designed to compare survival periods and response in three different modes of treatment for cancer of esophagus at CENAR Quetta i.e Radiotherapy plus Surgery, Radiotherapy plus Surgery plus single agent chemotherapy and Radiotherapy plus Surgery plus combined chemotherapy. Methods: During 1997, 59 patients with histopathological evidence of Ca esophagus were referred to CENAR from primary health care centers in Balochistan and Afghanistan. These 59 patients were divided into three groups. Group:I (n=22) treated by local irradiation plus surgery. Group:II (n=20) treated by local irradiation plus surgery plus Single agent chemotherapy i.e 5 florouracil. Group:III (n=17) treated by local irradiation plus surgery plus combination chemotherapy i.e Cis-Platinum and 5-florouracil. All patients were evaluated by endoscopic examination at 2 month intervals. Results: This study of 59 patients (mean age 55±13 years and male to female ratio of 1:3), shows that 2 year survival is 29% and median survival period is 9 month for all the patients. For group 1, median survival period = 5 month, 2 year survival =18% and complete response =17%. For group II, Median survival period = 9 months, 2 year survival =30% and complete response =20%. For group III, Median survival period = 11 month, 2 year survival = 41% and complete response = 22%.Conclusion: This study shows that overall survival is poor in cancer of esophagus and combined chemotherapy along with surgery and radiotherapy gives better results as compared to other two groups. Also single agent chemotherapy plus surgery plus radiotherapy give better results than radiotherapy plus surgery.Keywords: Ca Esophagus, Chemotherapy, Radiation therapy
Flood WA, Forester AA. Esophageal cancer: Current Opinion Oncology 1995:7:381-6
Brown LM, Swanson CA. Adenocarcinoma of the esophagus: role of obesity and diet. J Natl Cancer Inst 1995:87:104-9.
Fink U, Stein HU. Multimodal treatment for Squamous cell esophageal cancer. World J Surg 1995:19:198-204
Falk GW, Richter JE. Reflux disease and Barite's esophagus. Endoscopy 1996; 28:13-21.
Day NE, Varghese C. Esophageal cancer. Cancer Sure 1994; 19/20:43-54
Blot WJ Taylor PR. Esophageal cancer trends and risk factors. Seminars in Oncol 1994:403-10
Blot WJ, Taylor PR. Nutrition intervention trials in Linixian, China. J Natl Cancer Inst. 1993:85:1483-92
Cheng KK, Davies TW. Esophageal cancer mortality in Europe: paradoxical time trend in relation to smoking and drinking. Br J Cancer 1992; 65:613-7
Blot WJ, Devesa SS. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991; 265:1287-9
Lambert R. Endoscopic detection and treatment of early esophageal cancer. A critical analysis. Endoscopy. 1995;27:12-8
Azin F, Raie RM. Correlation between the levels of certain carcinogenic and anticarcinogenic trace elements and esophageal cancer in northern Iran. Ecotoxicol Environ Saf 1998; 39:179-84
Ries LAG, Miller BA. SEER Cancer Statistics Review, 1973-1991: Tables and Graphs, National Institute of H. NIH ubl. No 94-2789, Bethesda, MD, 1994
Akivama H. Edogawa H. Radical lymph node dissection for cancer of the thoracic esophagus. Ann Surg 1994;220:264-373
Kelson DP, Wilson DH. Chemotherapy and combined modality therapy for esophagus cancer. Chest 1995; 107:S224-S232